Infusion
Nursing Notes
By Nufactor

Infusion Nursing Notes by Nufactor provides education, resources and support to promote successful patient therapy within the infusion nursing community.

Administration, Common Side Effects and Dosing of INFLIXIMAB (REMICADE®)

By Candy Finley, RN, IgCN.

Infliximab is an intravenously administered genetically engineered monoclonal antibody that neutralizes inflammation caused by a protein called tumor necrosis factor alpha (TNFα) by binding to the soluble and transmembrane forms of TNFα with its receptors. Elevated concentrations of TNFα have been found in the tissues and fluids of patients with the Food and Drug Administration (FDA)-approved diagnoses. Infliximab controls the activity of several inflammatory chemicals. It is FDA-approved to treat rheumatoid arthritis, ankylosing spondylitis, Crohn's disease, plaque psoriasis, psoriatic arthritis and ulcerative colitis. Once established on treatment, symptoms should start to improve over a period of two to twelve weeks. [More]